TrialArthritis research & therapy2015

Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.

Josef S Smolen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.